Briana Hallman

Works (2)

Updated: July 5th, 2023 15:29

2019 journal article

Incidence and risk factors associated with development of clinical cardiotoxicity in dogs receiving doxorubicin

Journal of Veterinary Internal Medicine, 33(2), 783–791.

By: B. Hallman n, M. Hauck n, L. Williams*, P. Hess n  & S. Suter n

author keywords: canine; cardiology; cardiomyopathy; chemotherapy; echocardiography; oncology
MeSH headings : Animals; Antibiotics, Antineoplastic / administration & dosage; Antibiotics, Antineoplastic / adverse effects; Antibiotics, Antineoplastic / therapeutic use; Body Weight; Cardiomyopathy, Dilated / veterinary; Cardiotoxicity / veterinary; Dog Diseases / drug therapy; Dogs; Doxorubicin / administration & dosage; Doxorubicin / adverse effects; Doxorubicin / therapeutic use; Female; Heart Diseases / chemically induced; Heart Diseases / veterinary; Incidence; Male; Neoplasms / drug therapy; Neoplasms / veterinary; Retrospective Studies; Risk Factors
TL;DR: Overall, the incidence of clinical DOX‐induced cardiotoxicity is low, but Boxers and other breeds at high risk for dilated cardiomyopathy may be at an increased risk. (via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being (Web of Science; OpenAlex)
Sources: Web Of Science, ORCID, Crossref
Added: April 22, 2019

2017 journal article

The impact of carboplatin and toceranib phosphate on serum vascular endothelial growth factor (VEGF) and metalloproteinase-9 (MMP-9) levels and survival in canine osteosarcoma

Canadian Journal of Veterinary Research, 81(3), 199–205.

By: T. Gieger , J. Nettifee-Osborne, B. Hallman, C. Johannes, D. Clarke, M. Nolan, L. Williams

Source: NC State University Libraries
Added: August 6, 2018

Citation Index includes data from a number of different sources. If you have questions about the sources of data in the Citation Index or need a set of data which is free to re-distribute, please contact us.

Certain data included herein are derived from the Web of Science© and InCites© (2024) of Clarivate Analytics. All rights reserved. You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.